TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02695693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeachTown
Description: TeachTown is an online program for students with autism that uses an applied behavior analysis framework to provide intervention in academic and pre-academic areas

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discrete Trial Training
Description: Discrete trial training is a one-on-one didactic behavioral intervention in which the teacher or therapist uses specific behavioral methods based on principles of operant conditioning, to help students gain skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discrete Trial Training
Description: Discrete trial training is a one-on-one didactic behavioral intervention in which the teacher or therapist uses specific behavioral methods based on principles of operant conditioning, to help students gain skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pivotal Response Training
Description: Pivotal response training is a one-on-one child-lead behavioral intervention in which the teacher or therapist uses specific behavioral methods, leveraging the students interests, to help students gain skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Training
Description: Pivotal response training is a one-on-one child-lead behavioral intervention in which the teacher or therapist uses specific behavioral methods, leveraging the students interests, to help students gain skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teaching in Functional Routines
Description: Functional routines are sets of chained behaviors that students are taught that help them complete and manage specific activities in the classroom

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching in Functional Routines
Description: Functional routines are sets of chained behaviors that students are taught that help them complete and manage specific activities in the classroom
Study: NCT02689115

Intervention type: OTHER
Intervention: Genetic relative expression
Description: The genetic expression of NF-KB1 and IKK epsilon were quantified in both groups.

Intervention type: OTHER
Intervention: Genetic relative expression
Description: The genetic expression of NF-KB1 and IKK epsilon were quantified in both groups.
Study: NCT00751816

Intervention type: DRUG
Intervention: systemic chemotherapy

Intervention type: OTHER
Intervention: survey administration
Description: will be administered before, during, and after medical intent-to-cure treatment to describe head and neck cancer survivors' physical and functional well-being.

Intervention type: PROCEDURE
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Intervention: management of therapy complications
Study: NCT03029793

Intervention type: OTHER
Intervention: Functional Imaging analysis
Description: The SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI will be measures before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
Study: NCT00751816

Intervention type: PROCEDURE
Intervention: musculoskeletal complications management/prevention

Intervention type: PROCEDURE
Intervention: physical therapy
Description: weekly visits coordinated with adjuvant treatment as part of standard care

Intervention type: RADIATION
Intervention: radiation therapy
Study: NCT03848845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belantamab mafodotin
Description: belantamab mafodotin will be available as 20 milligrams per millilitre (mg/mL) solution for IV infusion, supplied as frozen liquid. belantamab mafodotin solution will be diluted in normal 0.9% saline to the appropriate concentration for the dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belantamab mafodotin
Description: belantamab mafodotin will be available as 20 milligrams per millilitre (mg/mL) solution for IV infusion, supplied as frozen liquid. belantamab mafodotin solution will be diluted in normal 0.9% saline to the appropriate concentration for the dose.
Study: NCT04201223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FLARE Intervention
Description: \[See arm/group descriptions\]
Study: NCT00589823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl citrate
Description: nasal spray, 100, 200, 400 or 800 mcg dosage according to need, to treat up to four episodes of BTCP per day
Study: NCT03848845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be available as 100 mg/4 mL solution that should be stored under refrigeration at 2-8 degree Celsius. Pembrolizumab injection (solution) will be diluted prior to IV administration in 0.9% sodium chloride injection or 5% dextrose injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be available as 100 mg/4 mL solution that should be stored under refrigeration at 2-8 degree Celsius. Pembrolizumab injection (solution) will be diluted prior to IV administration in 0.9% sodium chloride injection or 5% dextrose injection.
Study: NCT03430804

Intervention type: OTHER
Intervention: Bishop score calculation of modified Bishop score in numbers by digital vaginal examination
Description: Measurement of cervical length by transvaginal ultrasound and digital examination of Bishop score in 320 parturients undergoing labour induction at term
Study: NCT04111094

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study: NCT00589823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate release morphine sulphate
Description: drug dose as required by patient taken to treat up to four epsiodes of BTCP per day
Study: NCT04111094

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study: NCT01262885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: 500 mg tablet, dose levels detailed in Arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: 500 mg tablet, dose levels detailed in Arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: 500 mg tablet, dose levels detailed in Arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: 500 mg tablet, dose levels detailed in Arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: 500 mg tablet, dose levels detailed in Arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: 500 mg tablet, dose levels detailed in Arm description
Study: NCT01379911

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yogurt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yogurt
Study: NCT01670331

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological preparation
Description: Session 1: Help patients understand their relationship to food. Patients complete a 'food diary' as 'homework'. Give information about lifestyle changes after surgery. Presents the model of 'stress' and how it influences 'overeating', to develop a more balanced lifestyle and better QoL.~Session 2: 'Intervention' using Compassion Focussed Therapy model to understand relationship to food from their diary. Help develop a 'minimising overeating plan' (a 'relapse prevention' plan). Help learn to meet needs in other ways than food.~Session 3: Focus on physical body. Current body image, explore hopes and expectations for after surgery. Consider how to manage changes to social reactions and sexual relationships that may occur.
Study: NCT03978949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Licheniformis
Description: Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
Study: NCT01684930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training
Description: The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training
Description: The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
Study: NCT00383292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasisulam
Description: Tasisulam dose is dependent on participant's height, weight, and gender and is adjusted to target a specific Cmax based on participant laboratory parameters. Tasisulam is administered intravenously every 28 days until disease progression or other criteria for participant discontinuation are met.
Study: NCT04594122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improve hygiene practice of pork sellers
Description: includes 5 keys actions (Handbook) and provision of equipment incentive and training on good hygiene practices, branding, and certification
Study: NCT01508221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trental
Description: 400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 400IU twice daily starting the first day after last radiosurgery treatment and continuing for 6 months
Study: NCT03792230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Video group receive body mechanic education via CD material,

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brochure
Description: Brochure group receive body mechanic education via written material (brochure)
Study: NCT04190199

Intervention type: OTHER
Intervention: Observational
Description: Cross-sectional only

Intervention type: OTHER
Intervention: Observational
Description: Cross-sectional only

Intervention type: OTHER
Intervention: Observational
Description: Cross-sectional only
Study: NCT02708446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: 200mg oral mifepristone to both study arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: 200mg oral mifepristone to both study arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buccal misoprostol
Description: doses of buccal misoprostol every 3 hours beginning 24 hours after mifepristone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual misoprostol
Description: doses of sublingual misoprostol every 3 hours beginning 24 hours after mifepristone
Study: NCT00442741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone + Omeprazole
Study: NCT04371705

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes using ultrasound guide.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: placebo
Study: NCT04311515

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Tau Positron emission tomography (PET)
Description: Tau PET imaging enables the longitudinal assessment of the spatial pattern of tau deposition. Tau accumulates with progression of AD dementia and may be sensitive to disease related changes, particularly those due to intervention with a drug thought to work through a tau related mechanism. Quantitative assessments will be utilized to evaluate the target engagement and pharmacological effects of PU-AD after 6 months of treatment
Study: NCT00157209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single low dose cyclophosphamide
Description: A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
Study: NCT03060278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help materials
Description: Self-help smoking cessation materials.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help materials
Description: Self-help smoking cessation materials.
Study: NCT01262885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: 500 mg tablet, dose levels detailed in Arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2251052
Description: 500 mg tablet, dose levels detailed in Arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablet
Study: NCT04311515

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rating Scales
Description: Alzheimer's Disease composite score (ADCOMS+), CDR sb, Alzheimer's Disease Assessment Scale Cognitive (ADAS cog), Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS ADL), Mini Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale Cognitive (ADAS-COG 12)
Study: NCT02336945

Intervention type: DEVICE
Intervention: Abbott Sensor Based Glucose Monitoring System-Professional
Description: Subjects will wear 2 glucose sensors while going about daily activities and adhering to establish diabetes treatment plan. This is not a treatment study.
Study: NCT00371436

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Audiologic Tinnitus Management
Description: The five levels of progressive intervention are: (1) triage; (2) audiologic evaluation; (3) group education; (4) tinnitus evaluation; and (5) individual management.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Usual Care
Description: Typical audiologic care that would be received in a VA Audiology Clinic.
Study: NCT01469728

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-awake VATS talc pleurodesis
Description: Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake VATS talc pleurodesis
Description: Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
Study: NCT02304393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
Study: NCT03060278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: Participants who smoke \>10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg nicotine patches. Participants who smoke \< 10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patch
Description: Participants who smoke \>10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg nicotine patches. Participants who smoke \< 10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered automated treatment
Description: Tailored video clips, text and graphical messages delivered automatically each week to the participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Proactive phone counseling with a Certified Tobacco Treatment Counselor
Study: NCT02289794

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: E.coli bioconjugate vaccine
Description: Single dose, intramuscular injection (0.5 mL)
Study: NCT04311515

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rating Scales
Description: Alzheimer's Disease composite score (ADCOMS+), CDR sb, Alzheimer's Disease Assessment Scale Cognitive (ADAS cog), Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS ADL), Mini Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale Cognitive (ADAS-COG 12)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PU-AD
Description: PU-AD 30mg daily for 6mos

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 30mg daily for 6mos
Study: NCT01005966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride Toothpaste
Description: Test product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amine Fluoride Toothpaste
Description: Test product
Study: NCT02304393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
Study: NCT01005966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate/Sodium Fluoride Toothpaste
Description: test product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo and washout treatment

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo and washout treatment

Intervention type: DRUG
Group type: OTHER
Intervention: 675 ppmf toothpaste
Description: dose response
Study: NCT03616782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib 3mg on day 1, 8, 15 q 4 weeks for 24 months or until progression
Study: NCT01262885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablet
Study: NCT02304393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selicrelumab
Description: Selicrelumab will be administered as per the dosage regimen mentioned in respective arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selicrelumab
Description: Selicrelumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
Study: NCT00983125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Addition of a non-labeled drug (clonidine) in one of the two arm of the study, with randomisation.~To compare the effects of a systematic addition of clonidine (150 µg added in the solution bag) in the local anesthetic solution), versus no addition, on the quality of analgesia for labour.

Intervention type: DRUG
Group type: OTHER
Intervention: Clonidine
Description: Addition of a non-labeled drug (clonidine) in one of the two arm of the study, with randomisation.~To compare the effects of a systematic addition of clonidine (150 µg added in the solution bag) in the local anesthetic solution), versus no addition, on the quality of analgesia for labour.
Study: NCT01654666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic preconditioning
Description: Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Artery Stenting
Description: Carotid Artery Stenting is an invasive therapy of carotid artery stenosis.
Study: NCT03409237

Intervention type: DRUG
Intervention: Mannitol
Description: Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity \<320.

Intervention type: DRUG
Intervention: Hypertonic saline solution
Description: Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity \<320.

Intervention type: DRUG
Intervention: Hypertonic saline solution
Description: Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity \<320.

Intervention type: DRUG
Intervention: Hypertonic saline solution
Description: Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity \<320.
Study: NCT01756027

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System providing one treatment per cheek
Description: Focused ultrasound energy delivered below the surface of the skin per cheek.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System providing two treatments per cheek
Description: Focused ultrasound energy delivered below the surface of the skin
Study: NCT01306266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rizatriptan
Description: initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo. Drug is to be taken at onset of a moderate or severe headache

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg at onset of a moderate or severe headache.
Study: NCT03693417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated circuit on
Description: Heated circuit will be turned on.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated circuit off
Description: Heated circuit will be turned off.
Study: NCT03298542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants will receive subcutaneous golimumab for 26 weeks, where doses will be based on weight and/or body surface area.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to golimumab.